WHO ICTRP trial
Efficacy and Safety of Pramipexole as an augmenting agent for Major Depressive…
CTRI/2024/12/078604 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2024/12/078604 |
|---|---|
| Public title | Efficacy and Safety of Pramipexole as an augmenting agent for Major Depressive Disorder. |
| Scientific title | Efficacy and Safety of Pramipexole as an augmenting agent for Major Depressive Disorder- A Pragmatic Trial. - NIL |
| Primary sponsor | Dr Vincent Soram |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features |
| Interventions | Intervention1: SSRIs plus Pramipexole: (0.375mg/day starting dose and maximaly titrated ot 4.5mg/day based on tolerability and clinical assessments over 8 weeks Control Intervention1: SSRI + placebo: give placebo |
| Registration date | Dec 26, 2024 |
| Target size | 70 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: